The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.

The vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5%. This market is segmented based on product type, route of administration, disease type, applications, and application category.

Based on disease type, the vaccine adjuvants market comprises of infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global market in 2016. High prevalence of infectious diseases and cancer is expected to drive market growth in the coming years.

Based on applications, the vaccine adjuvants market is segmented into research applications and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to factors such as ongoing research on new adjuvants, increasing initiatives by government bodies and companies, usage of many vaccine adjuvants commercially, increasing incidences of zoonotic diseases, and increase in the number of conferences and summits.

Get more Information: https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html

Based on geography, the global vaccine adjuvants market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India. Rising prevalence of infectious diseases, increasing government investments for vaccine research and development, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian region.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]